CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
识别弥漫大 B 细胞淋巴瘤中 CAR-T 细胞疗法疗效与安全性结局预后因素的系统文献综述
英文原题：Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.
查看英文原题
Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
本综述的发现可帮助临床医生通过纳入这些关键影响因素，优化治疗策略并改善 DLBCL 患者的结局。
研究思路结论见上方概要
目的
通过系统文献综述，识别并总结影响弥漫性大B细胞淋巴瘤（DLBCL）患者CAR-T 细胞治疗疗效和安全性结局的临床因素。
方法
我们进行了一项系统性文献综述，以确定影响CAR-T 疗法在DLBCL中疗效和安全性的因素。在PubMed、Cochrane和EMBASE数据库中检索了文章。根据PRISMA指南提取了关键结局指标，包括无进展生存期（PFS）、总生存期（OS）、完全缓解率（CRR）、客观缓解率（ORR）、缓解持续时间（DoR）、最佳总体缓解（BOR）以及安全性指标（如免疫效应细胞相关神经毒性综合征[ICANS]和细胞因子释放综合征[CRS]）。共检索到712篇文章，其中185篇被选中进行全文筛选。最终，79篇文章符合纳入标准。排除的主要原因是没有相关结局数据或发表类型不符。
结果
本综述重点阐述了可能影响CAR-T 疗法在DLBCL中疗效和安全性的若干因素，包括东部肿瘤协作组体能状态评分（ECOG PS）、国际预后指数（IPI）评分、疾病组织学、Ann Arbor疾病分期以及LDH水平升高。
展开英文摘要原文
PURPOSE
To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review.
METHODS
We performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type.
RESULTS
This review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels.
CONCLUSION
The findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
论文信息
- 作者
- Schleifenbaum JK、Heger JM、Jost J、Rosato U、Riou S、Borchmann P、Walzer S、Mahlich J
- 第一作者单位
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany.Germany
- 通讯作者单位
- Miltenyi Biomedicine, Friedrich-Ebert-Straße 68, 51429, Bergisch Gladbach, Germany. Joerg.Mahlich@gmail.com.Germany
- 文献类型
- 系统综述
- 期刊
- Journal of cancer research and clinical oncology2025 Jul 7
- 原文标识
- PubMed 40619472 · DOI 10.1007/s00432-025-06249-z
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →